Kissei gets rights to develop and market avacopan in Japan

9 June 2017

Japanese drugmaker Kissei Pharmaceutical (TYO: 4547) has been granted exclusive rights to develop and commercialize avacopan (CCX168) in Japan by Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a joint venture between Switzerland’s Vifor Pharma (VTX: VIFN) and Fresenius Medical Care.

Under the terms of the agreement, Kissei will have the exclusive right to develop avacopan in Japan and, once marketing authorization has been granted, commercialize it in that country. VFMCRP will remain responsible for marketing avacopan everywhere else outside the USA and China, where it is commercialized by US biopharmaceutical company and Vifor Pharma licensor, ChemoCentryx.

The agreement with Kissei comes only two months after ChemoCentryx granted VFMCRP a territory expansion into Japan, which underscores the unmet medical need there and the potential of avacopan for treating it.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK